Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Navigate: Correlations HPO
There is one clinical trial.
Study population: Patients with fibrotic lung sequelae after recovery from acute phase of severe COVID19 pneumonia Objectives: To evaluate the effect of pirfenidone administered for 24 weeks in patients who have pulmonary fibrotic changes after suffering severe COVID19 pneumonia, analysed by - % change in forced vital capacity (FVC) - % fibrosis in high resolution computed tomography (HRCT) of the lung
Description: To investigate the effect of pirfenidone administered for 24 weeks measuring the number of patients who have pulmonary fibrotic changes from baseline after suffering severe COVID19 pneumonia, analysed by Change From Baseline in % in forced vital capacity (FVC) Change From Baseline % fibrosis in high resolution computed tomography (HRCT) of the lung
Measure: To investigate the effect of pirfenidone on fibrotic signs induced by COVID19 infection Time: 24 weeksDescription: Number of patients who show maintenance of stability or functional improvement: stability will be considered when the FVC does not increase more than 10% or does not decrease more than 10% and the DLCO does not increase more than 15% or decreases more than 15%. An increase in% FVC greater than 10% or in DLCO greater than 15% will be considered significant improvement.
Measure: Maintenance of stability or functional improvement FVC Time: 24 weeksDescription: Rate of decreased oxygen requirement for physical activity in patients
Measure: Decreased oxygen requirement for physical activity Time: 24 weeksDescription: Number of patients who have improved exercise capacity (> 50 meter improvement or less decrease in% oxygen saturation) in the TM6m
Measure: Improved exercise capacity (> 50 meter improvement or less decrease in% oxygen saturation) in the TM6m Time: 24 weeksDescription: Number of Hospitalizations (general and due to respiratory problems)
Measure: Hospitalizations (general and due to respiratory problems) Time: 24 weeksDescription: Number of Visits to the Emergency or Day Hospital for respiratory causes
Measure: Visits to the Emergency or Day Hospital for respiratory causes Time: 24 weeksDescription: Number of patients who need Lung transplantation
Measure: Lung transplantation Time: 24 weeksDescription: Number of patients who die
Measure: Death Time: 24 weeksAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports